Mi­rati’s drug sitra­va­tinib flops PhI­II in com­bo with Op­di­vo for cer­tain lung can­cer

Mi­rati Ther­a­peu­tics’ path to a sec­ond drug ap­proval will like­ly have to wait. The San Diego biotech com­pa­ny said Wednes­day that its in­ves­ti­ga­tion­al lung can­cer drug failed a Phase III tri­al test­ing it in com­bi­na­tion with Bris­tol My­ers Squibb’s Op­di­vo.

The drug, sitra­va­tinib, and Op­di­vo weren’t bet­ter than the chemo drug do­c­etax­el at keep­ing pa­tients alive, Mi­rati said in a press re­lease. The spec­trum-se­lec­tive ki­nase in­hibitor missed the pri­ma­ry goal of over­all sur­vival in pa­tients with sec­ond- or third-line ad­vanced non-squa­mous, non-small cell lung can­cer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN